Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis

BACKGROUND: Bevacizumab (Avastin(®)), a monoclonal antibody targeting vascular endothelial growth factor (VEGF)-A, is widely used in treating a variety of malignant tumors. Several biosimilars of bevacizumab have been developed and marketed with the expiration of bevacizumab’s patent. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xian, Zhang, Guixing, Sun, Binxu, Wang, Chaoran, Wang, Xiaoqun, Kong, Fanming, Jia, Yingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273685/
https://www.ncbi.nlm.nih.gov/pubmed/35836506
http://dx.doi.org/10.21037/tcr-22-71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273685/
https://www.ncbi.nlm.nih.gov/pubmed/35836506
http://dx.doi.org/10.21037/tcr-22-71

Ejemplares similares